CDC: Antibiotic Resistant Shigella Becoming Higher Risk in US

Key Takeaways

• XDR Shigella isolates rose to 8.5% in 2023
• 86% of XDR cases occurred in men, median age 41
• 46% of XDR patients were HIV‑positive, increasing risk
• No FDA‑approved oral drugs exist for XDR Shigella
• Surveillance via PulseNet identified 510 XDR isolates since 2011

Pulse Analysis

Shigellosis, a fecal‑oral and sexually transmitted diarrheal disease, has long been managed with a suite of oral antibiotics. Over the past decade, however, the pathogen’s genetic adaptability has outpaced drug development, leading to the emergence of extensively drug‑resistant (XDR) strains. The CDC’s PulseNet network, which aggregates whole‑genome sequencing data from clinical labs, now flags a worrying trend: XDR Shigella accounts for nearly one‑tenth of all isolates in 2023, a stark contrast to its absence a decade earlier. This shift underscores how bacterial evolution can quickly render standard therapies ineffective, raising alarms for clinicians and public‑health officials alike.

The demographic profile of the XDR outbreak reveals a concentration among adult men, with a median age of 41, and a significant overlap with HIV infection—46% of patients with known status were HIV‑positive. These factors suggest both behavioral and immunological vulnerabilities that facilitate transmission and complicate treatment. With no FDA‑approved oral antimicrobial agents for XDR Shigella, physicians are forced to rely on intravenous options, hospital admissions, and supportive care, inflating costs and straining resources. The lack of outpatient therapies also hampers efforts to curb community spread, especially in settings like men‑who‑have‑sex‑with‑men networks where close contact accelerates outbreaks.

Addressing the XDR surge requires a multi‑pronged strategy. Strengthened surveillance through PulseNet and rapid genomic reporting can pinpoint hotspots and guide targeted interventions. Public‑health campaigns must emphasize hygiene, safe sexual practices, and early testing, particularly for high‑risk groups. Meanwhile, the pharmaceutical pipeline faces a clear market incentive to develop novel oral agents or repurpose existing drugs with activity against resistant Shigella. Investment in antimicrobial research, coupled with stewardship programs, will be essential to prevent XDR Shigella from becoming a entrenched public‑health crisis.